Does anyone know if GSK drug CAB-ULA is the same

Does anyone know if GSK drug CAB-ULA is the same as HIV (ULA Q4/Q6M)? It doesn’t appear to be, but I’m just thinking Q4/Q6M ultra long-acting is cabotegravir. I don’t see anything specificity stating that but I just started looking based on GSK newest PR and I don’t see HIV (ULA Q4/Q6M) really mentioned before today.

“5 major new product approvals expected in 2025 including: Blenrep (multiple myeloma) and depemokimab (severe asthma and CRSwNP(1)); plus phase III readouts: camlipixant (refractory chronic cough) and tebipenem (complicated UTI); and important pipeline catalysts: Respiratory (depemokimab COPD); Oncology (B7-H3 & B7-H4 ADCs); HIV (ULA Q4/Q6M)”

https://www.gsk.com/en-gb/media/press-release...-outlook/3


Looking at their pipeline now.

https://www.gsk.com/media/11766/4q2024-pipeline-list.xlsx

https://www.sec.gov/Archives/edgar/data/11313...5-0225.htm

Alright, looks like this is the first time it’s been mentioned. I searched a bunch of spots and this 6k was the latest filing and it mentioned their new long-acting HIV drug which appears to be unknown drug at the time of my writing.

Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565


Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program

⸻

Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com